Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

• Status: Not yet recruiting
• Trial end date: 2023-08-01

Summary

The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

• Phase: Phase 4

Details

• Lead Sponsor: Shandong University
• Collaborators: Heze Municipal 3rd people's hospital; Jining No.2 People's Hospital; Maternity and Child Care Health Center of Dezhou; PKUcare luzhong hospital; Qihe County City Hospital; Qilu Hospital of Shandong University; Shandong Electric Power Central Hospital; Shandong Provincial Third Hospital; Taian City Central Hospital; The Affiliated Hospital of Qingdao University; The People's Hospital of Guangrao; Weifang People's Hospital; Weihai Municipal Hospital; Yuncheng Chengxin Hospital; Zoucheng People's Hospital
• Treatments: Amoxicillin; Bismuth; Clarithromycin; Metronidazole; Potassium Citrate; Tetracycline